title: [Regulation of intracellular lipid metabolism by the preparation of omega-3 phospholipids from marine organisms in deficiency of essential fatty acids in rats].
abstract: It has been established that a deficit of essential fatty acids (EFA) in the animal organism induces specific modifications of composition of fatty acid (FA) of general phospholipids and plasmalogenic P1 in microsomal tissue membranes with various functions and affects the activity of phospholipase A2. It has been shown that arachidonic (AA), docosapentaenoic (DPA) and docosahexaenoic (DHA) acids in the composition of general phospholipids - phosphatidylcholine (PC), phosphatidylethanolamine (PEA) and plasmalogens PC and PEA react to EFA deficit in the organism. Quantitative redistribution of AA, DPA, DHA of FA in general phospholipids and plasmalogenic microsomal membranes depending on their functions was found under EFA deficit in the organism. Deficit of DHA and plasmalogenic phospholipids evidences that the status of cell plasmalogens affects the level of PUFA at EFA deficit in the organism. AA and DHA can be a selective target for plasmalogens. The drug of omega-3 phospholipids, considerable amount of DHA and eicosapentaenoic (EPA)FA being present in their structure, increases the amount of plasmalogens and decreases the amount of AA in the brain, heart and reproductive organs. It was also found that EFA deficit in the organism favours the increase of lisoPEA, lisoPC, free FA (FFA) connected with the increase of activity of endogenic phospholippase A2 and plasmalogen-selective phospholipase A2. The omega-3 phospholipase from marine organisms at EFA defecit decreases the amount of FFA, lisophospholipids and activity of phospholipase A2 in the microsomas of the studied tissues. The drug of omega-3 phospholipids normalizes the state and functions of the brain, liver, and heart tissues, reproductive organs against a background of EFA defecit and regulates the synthesis of biologocically active metabolites of AA in the organism.
authors.forename: P V
authors.initials: PV
authors.lastname: Cherniavs'kyĭ
authors.forename: Z M
authors.initials: ZM
authors.lastname: Datsenko
authors.forename: L H
authors.initials: LH
authors.lastname: Moiseieva
authors.forename: N V
authors.initials: NV
authors.lastname: Kanivets'
authors.forename: O P
authors.initials: OP
authors.lastname: Kozulina
authors.forename: A M
authors.initials: AM
authors.lastname: Boroda
authors.forename: O S
authors.initials: OS
authors.lastname: Abakumova
mesh_terms: D000818:Animals; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D005228:Fatty Acids, Essential / Q000172:deficiency*; D015525:Fatty Acids, Omega-3 / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D008386:Marine Biology; D008861:Microsomes / Q000187:drug effects* / Q000378:metabolism; D009928:Organ Specificity; D010743:Phospholipids / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats
chemical_list: D005228:Fatty Acids, Essential; D015525:Fatty Acids, Omega-3; D010743:Phospholipids